The proposed activities will inform clinicians of recent evidence from clinical trials on the efficacy and safety of TROP2-directed antibody-drug conjugates (ADCs) in patients with progressive NSCLC, allowing them to quickly integrate new treatments into their practice when they become available. Clinicians will be updated on HER2 genomic alterations and apply appropriate testing methodologies per the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. Furthermore, participants will receive education on the successful management of NSCLC, including managing brain metastases, optimal HER2-targeted ADC dosing, and monitoring approaches for treatment-related adverse events (AEs). Finally, the proposed activities aim to educate participants on the importance of targeting HER3 and using HER3-directed ADCs in the management of NSCLC. The initiative will also provide information on the efficacy and safety of these ADCs based on clinical trial data, as well as strategies for recognizing and minimizing treatment-related AEs to enhance therapy adherence and improve patient outcomes.

CME/CE Accreditation Information

In the United States, obesity and overweight are an epidemic and a major health concern worldwide. Excess adipose tissue can lead to diabetes, hypertension, cardiovascular disease, certain cancers, poor mental health, and musculoskeletal disorders, resulting in decreased quality of life and increased mortality. While lifestyle modifications are a cornerstone of obesity and overweight management, most patients do not achieve durable results, highlighting a need for pharmacological interventions. This educational curriculum will help primary care clinicians identify patients with obesity who could benefit from weight-loss medicines and integrate evidence-based strategies for motivational interviewing and shared decision-making to improve outcomes for patients with obesity.

CME/CE Accreditation Information